Issue 7, 2022

A bone-targeting drug delivery vehicle of a metal–organic framework conjugate with zoledronate combined with photothermal therapy for tumor inhibition in cancer bone metastasis

Abstract

Chemotherapy is a conventional treatment method for metastatic bone cancer, but it has limitations, such as lower drug-targeting of bone tissues and serious side effects. Bone metastasis almost always occurs in advanced cancer, and most patients in this period have strong drug resistance, which further worsens the curative effect. To address the above-mentioned difficulties, a drug delivery platform is proposed in this paper that accomplishes the bone-targeting of drugs to efficiently inhibit tumors. First, the anti-cancer drugs 5-fluorouracil (5-Fu) and indocyanine green (ICG) were loaded into a zeolitic imidazolate framework (ZIF-90) to form 5-Fu/ICG@ZIF-90. Polyethylene glycol with zoledronic acid (ZOL) was encapsulated using 5-Fu/ICG@ZIF-90 to synthesize 5-Fu/ICG@ZIF-90-PEG-ZOL nanoparticles, which showed dimensional stability, good thermal stability, and bone-targeting ability. Second, the in vitro anti-cancer activity of the designed platform was investigated using cytotoxicity, apoptosis, live–dead staining, cell cycle, and cell ultrathin section analysis. The results indicated that the nanoparticles inhibited MCF-7 cell activity when chemotherapy was combined with PTT. Finally, H&E staining and TUNEL detection were performed in mouse organs and tumors. The nanoparticles combined with photothermal therapy (PTT) and triggered by near-infrared irradiation induce apoptosis of tumor cells in vivo, displaying a better efficacy of combined chemotherapy and photothermal therapy. Experiments conducted on the 5-Fu/ICG@ZIF-90-PEG-ZOL nanoparticles demonstrated their promising performance for cancer bone metastasis inhibition.

Graphical abstract: A bone-targeting drug delivery vehicle of a metal–organic framework conjugate with zoledronate combined with photothermal therapy for tumor inhibition in cancer bone metastasis

Supplementary files

Article information

Article type
Paper
Submitted
08 Nov 2021
Accepted
21 Jan 2022
First published
07 Mar 2022

Biomater. Sci., 2022,10, 1831-1843

A bone-targeting drug delivery vehicle of a metal–organic framework conjugate with zoledronate combined with photothermal therapy for tumor inhibition in cancer bone metastasis

T. Ge, Z. Weiwei, F. Ge, L. Zhu, P. Song, W. Li, L. Gui, W. Dong, Y. Tao and K. Yang, Biomater. Sci., 2022, 10, 1831 DOI: 10.1039/D1BM01717A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements